Canada's Victory Square Q2 revenue jumps on Hydreight strength
Canada's Victory Square Q2 revenue jumps on Hydreight strength
Overview
Canada venture builder's Q2 revenue rose 421% yr/yr to C$28.0 mln, driven by Hydreight
Q2 net income increased to C$2.5 mln from C$0.4 mln a year earlier
Company attributes growth to Hydreight and fair-value adjustments in portfolio investments
Outlook
Hydreight reaffirms fiscal 2026 revenue guidance of approximately $150 mln
Company prioritizes supporting Hydreight's growth and advancing healthcare investments in second half 2026
Company maintains focus on disciplined capital allocation across its portfolio
Result Drivers
HYDREIGHT GROWTH - Co said Q2 revenue growth was primarily driven by Hydreight Technologies' expansion in U.S. healthcare infrastructure and pharmacy operations
PHARMACY SALES IMPACT - Hydreight's pharmacy product sales increased and changed revenue mix, contributing to lower gross margin due to pricing concessions
FAIR-VALUE ADJUSTMENTS - Co said net income was also attributable to fair-value adjustments in portfolio investments
Company press release: ID:nPn697q2ka
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue |
| C$28 mln |
|
Reuters Recommended Reads
Aug 31 - Canada's Greenway Q1 revenue rises on record cannabis sales volume
Aug 31 - Canadian natural sweetener supplier GLG Life Tech's Q2 revenue falls on lower prices, sales volumes
Aug 31 - Canada's Avante Logixx Q1 revenue rises 14%, Adjusted EBITDA more than doubles
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Victory Square Technologies
See all newsCanada's Victory Square Q2 revenue jumps on Hydreight strength
Brief: Victory Square Provides Update On Hydreight And Healthcare Investments Following FDA Advisory Committee Recommendations On Peptide-Related Bulk Drug Substances
Brief: Victory Square Provides Update On Hydreight And Healthcare Investments Following FDA Advisory Committee Recommendations On Peptide-Related Bulk Drug Substances
Brief: Victory Square Technologies Declares Special Common Share Dividend Of Its Interest In Yocale.ai
Brief: Hydreight Technologies Signs Binding Letter Of Intent To Acquire Dynamic Iv Therapy Support Ai Agent